What the business is, and whether it's a good one at a fair price.
Manufactures and sells pharmaceutical formulations, with 97.6% of standalone turnover coming from exports across 65 countries. Operates 6 manufacturing plants in India across 14 states, four of which are zero liquid discharge facilities, supported by a workforce of 1,907 employees and 908 workers. Formulation volumes rose 131% and standalone revenue grew 84% over the current MD's tenure, reaching Rs 1,475 crore in FY26; on a consolidated basis, total income was Rs 2,201.85 crore with net profit of Rs 252.84 crore. Related party sales accounted for 65.59% of revenue, with material supplies received from a step-down subsidiary. The company's largest cost line is materials at 34.9% of revenue, followed by employees at 18.0% and other operating expenses at 27.3%. EBITDA margin stood at 20.4% in FY26.
Measured from the filed financials, judged against its Pharmaceuticals peers · as of FY26 — not investment advice
How has the market priced it — with filings on the timeline?
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
How does it stack up on valuation, returns and growth?
Loading peers…
Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.
Loading financials…
Who owns it — and is the promoter stake clean?
Loading shareholding…
Sign up to see the full company file
Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.
Answered from UNICHEM LABORATORIES LTD's filed financials and exchange disclosures
UNICHEM LABORATORIES LTD is a Pharmaceuticals & Biotechnology company listed on NSE and BSE, trading under the symbol UNICHEMLAB.
Yes. Over the trailing twelve months UNICHEM LABORATORIES LTD reported a net profit of ₹305 Cr on revenue of ₹2,308 Cr.
Not in the latest reported year — UNICHEM LABORATORIES LTD's dividend payout for FY26 was nil.
No. Debt stands at 0.17× equity, and it carries net debt of ₹179 Cr. That is lower than 45% of its 171 Pharmaceuticals peers.
On trailing P/E, UNICHEM LABORATORIES LTD ranks 30 of 169 in Pharmaceuticals — cheaper than 83% of them, against an industry median of 28.9×. This is a position, not a valuation judgement.
On a typical session UNICHEM LABORATORIES LTD moves 1.44% — that is the median absolute close-to-close move across its last 268 trading days. Announcement days are routinely larger.
Every NSE and BSE filing by UNICHEM LABORATORIES LTD appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.
Figures are as last reported and may lag the latest filing. Not investment advice.
